AtaiBeckley completes dosing in Phase 2b depression trial, expects topline data in Q4
July 6, 2026 · High impact · Updated Jul 20, 2026
Atai Life Sciences (ATAI) and Beckley Psytech have completed dosing in their Phase 2b clinical trial for a depression treatment. Topline data from this trial is anticipated in the fourth quarter of the current year.
Affected Companies
AlphaOS aggregates and analyzes market news to extract structured investment intelligence. Content is for research and education only — not investment advice.